136 related articles for article (PubMed ID: 16491719)
1. The pediatrician's dilemma.
Nelson LB
J Pediatr Ophthalmol Strabismus; 2006; 43(1):13. PubMed ID: 16491719
[No Abstract] [Full Text] [Related]
2. Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
Med Lett Drugs Ther; 2004 Mar; 46(1179):25-7. PubMed ID: 15057188
[No Abstract] [Full Text] [Related]
3. Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.
Keating GM
Drugs; 2011 Jan; 71(1):89-99. PubMed ID: 21175242
[TBL] [Abstract][Full Text] [Related]
4. [Conjunctivitis due to Achromobacter xylosoxidans: case report].
Lucatelli JF; Cantarelli VV; Picoli SU
Arq Bras Oftalmol; 2009; 72(2):261-3. PubMed ID: 19466343
[TBL] [Abstract][Full Text] [Related]
5. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
[TBL] [Abstract][Full Text] [Related]
6. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
Granet DB; Dorfman M; Stroman D; Cockrum P
J Pediatr Ophthalmol Strabismus; 2008; 45(6):340-9. PubMed ID: 19043945
[TBL] [Abstract][Full Text] [Related]
7. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin versus polymyxin B/trimethoprim sulfate in pediatric bacterial conjunctivitis.
Wagner RS
J Pediatr Ophthalmol Strabismus; 2008; 45(6):330. PubMed ID: 19043943
[No Abstract] [Full Text] [Related]
10. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Bertino JS; Zhang JZ
Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
[TBL] [Abstract][Full Text] [Related]
11. Controlling contagious bacterial conjunctivitis.
Lichtenstein SJ; Dorfman M; Kennedy R; Stroman D
J Pediatr Ophthalmol Strabismus; 2006; 43(1):19-26. PubMed ID: 16491721
[TBL] [Abstract][Full Text] [Related]
12. A case of vancomycin-resistant enterococcus conjunctivitis and its clinically successful topical treatment.
Maguen E; Morgan MA
Cornea; 2007 Feb; 26(2):223-4. PubMed ID: 17251818
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of moxifloxacin in treating bacterial conjunctivitis: a meta-analysis].
Kodjikian L; Lafuma A; Khoshnood B; Laurendeau C; Berdeaux G
J Fr Ophtalmol; 2010 Apr; 33(4):227-33. PubMed ID: 20223557
[TBL] [Abstract][Full Text] [Related]
14. A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children.
Williams L; Malhotra Y; Murante B; Laverty S; Cook S; Topa D; Hardy D; Wang H; Gigliotti F
J Pediatr; 2013 Apr; 162(4):857-61. PubMed ID: 23092529
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
16. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin punctum plug for sustained drug delivery.
Chee SP
J Ocul Pharmacol Ther; 2012 Aug; 28(4):340-9. PubMed ID: 22191856
[TBL] [Abstract][Full Text] [Related]
18. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Silver LH; Woodside AM; Montgomery DB
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
[TBL] [Abstract][Full Text] [Related]
19. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
20. Stenotrophomonas maltophilia endocarditis treated with moxifloxacin-ceftazidime combination and annular wrapping technique.
Sanioğlu S; Sokullu O; Yavuz SS; Kut MS; Palaz FK; Bilgen FS
Anadolu Kardiyol Derg; 2008 Feb; 8(1):79-80. PubMed ID: 18258545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
